Skip to content
Piperazine
Antepar, Bryrel, Multifuge, Vermidol (piperazine) is a small molecule pharmaceutical. Piperazine was first approved as Multifuge on 1982-01-01. It is used to treat ascariasis, enterobiasis, and nematode infections in the USA. It is known to target 5-hydroxytryptamine receptor 2B, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, 5-hydroxytryptamine receptor 1D, muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1E, muscarinic acetylcholine receptor M5, 5-hydroxytryptamine receptor 7, muscarinic acetylcholine receptor M1, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Piperazine citrate
Tradename
Company
Number
Date
Products
MULTIFUGEBluline LaboratoriesN-009452 DISCN1982-01-01
1 products
ANTEPARGSKN-009102 DISCN1982-01-01
2 products
BRYRELSanofiN-017796 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ascariasisEFO_0007154D001196B77
enterobiasis—D017229B80
nematode infections—D009349B77
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AB: Phenothiazines with piperazine structure, antipsychotics
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02C: Antinematodal agents
— P02CB: Piperazine and derivatives, antinematodal agents
— P02CB01: Piperazine
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DA: Xanthines, systemic for obstructive airway disease
— R03DA09: Acefylline piperazine
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AE: Piperazine derivatives, systemic antihistamines
HCPCS
No data
Clinical
Clinical Trials
101 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Septic shockD012772A48.3——3249
SepsisD018805A41.91—1248
Urinary tract infectionsD014552EFO_0003103N39.0—23217
Bacterial infectionsD001424A491——517
PneumoniaD011014EFO_0003106J18—12126
InfectionsD007239EFO_00005441—1125
Febrile neutropeniaD064147—2—3—5
Cystic fibrosisD003550EFO_0000390E84———224
AppendicitisD001064EFO_0007149K37———314
Enterobacteriaceae infectionsD004756EFO_1001313———314
Show 14 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16—22——3
Intraabdominal infectionsD059413—12——2
Ventilator-associated pneumoniaD053717EFO_1001865J95.851——2——2
NeoplasmsD009369C80—11——2
LeukemiaD007938C95——1—12
Hematologic neoplasmsD019337——1—12
LymphomaD008223C85.9——1—12
Surgical wound infectionD013530——1——1
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Pancreatic diseasesD010182K86.9——1——1
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Critical illnessD016638—1——34
Systemic inflammatory response syndromeD018746EFO_1001478R65.10—1——12
Gastrointestinal microbiomeD000069196—1———1
Otitis mediaD010033EFO_0004992H66.911———1
Graft vs host diseaseD006086D89.81—1———1
Cross infectionD003428—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4———15
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neonatal sepsisD000071074HP_0040187————22
NeutropeniaD009503D70————22
Hematopoietic stem cell transplantationD018380————22
Gram-positive bacterial infectionsD016908————22
Cytokine release syndromeD000080424D89.83————11
Viral pneumoniaD011024EFO_0007541J12.9————11
Chronic bronchitisD029481J42————11
Cerebral hemorrhageD002543————11
Subarachnoid hemorrhageD013345EFO_0000713I60————11
Drug monitoringD016903————11
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePIPERAZINE
INN—
Description
Piperazine is an azacycloalkane that consists of a six-membered ring containing two nitrogen atoms at opposite positions. It has a role as an anthelminthic drug. It is a saturated organic heteromonocyclic parent, an azacycloalkane and a member of piperazines. It is a conjugate base of a piperazinium(2+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C1CNCCN1
Identifiers
PDB—
CAS-ID110-85-0
RxCUI8340
ChEMBL IDCHEMBL1412
ChEBI ID28568
PubChem CID4837
DrugBankDB00592
UNII ID—
Target
Agency Approved
No data
Alternate
HTR2B
HTR2B
CHRM4
CHRM4
CHRM3
CHRM3
HTR1D
HTR1D
CHRM2
CHRM2
HTR2A
HTR2A
HTR2C
HTR2C
HTR1E
HTR1E
CHRM5
CHRM5
HTR7
HTR7
CHRM1
CHRM1
HTR6
HTR6
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
3357
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Q6P523
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 28,862 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,911 adverse events reported
View more details